lino Biotech

lino Biotech developed Focal Molography®, a patented nanotechnology-based biosensing method enabling robust, label-free measurement of molecular interactions directly in living cells or complex biological samples. Their platforms support high-throughput hit validation from DNA encoded libraries, binder development/characterization in biologically relevant environments, target identification in live cells, and quality control during cell/gene therapy manufacturing. The company's technologies help lower R&D costs by providing faster and more accurate data to pharma/biotech customers. In February/March 2023 they were acquired by Miltenyi Biotec; their Zurich site continues as an R&D hub within the parent organization.